S-1/A: Allurion Technologies Files for Offering of Common Stock and Warrants

Allurion Technologies is seeking to raise capital through an offering of common stock, pre-funded warrants, and common stock purchase warrants.

Summary

• Allurion Technologies is offering up to 3,926,701 shares of common stock, or pre-funded warrants in lieu thereof, along with Series A and Series B common stock purchase warrants.
• Each share of common stock comes with one Series A warrant exercisable for 1.5 shares and one Series B warrant exercisable for one share.
• The Series B warrants also have an alternative cashless exercise provision where the holder can receive three shares for each share they would have received in a cash exercise.
• The warrants will be exercisable after the Stockholder Approval Date and will expire five years from the Initial Exercise Date.
• Pre-funded warrants are offered as an alternative to common stock for purchasers who would otherwise exceed a 4.99% (or 9.99%) ownership threshold.
• Each pre-funded warrant is exercisable for one share of common stock at a price of $0.0001 per share.
• The offering is expected to close on January 31, 2025, unless terminated earlier.
• Certain funds affiliated with RTW Investments, LP have indicated an interest in investing $1.5 million in this offering and a concurrent private placement of preferred stock and warrants.

Sentiment

Score: 6

Explanation: The document is a standard offering document, with no strong positive or negative sentiment. The company is seeking to raise capital, which is a normal business activity.

Positives

• The offering provides flexibility for investors with the option to purchase pre-funded warrants instead of common stock.
• The Series B warrants offer an alternative cashless exercise option, potentially increasing the number of shares received by the holder.
• The company is seeking to raise capital to fund its commercial sales, research and development, and for working capital and other general corporate purposes.

Negatives

• The warrants are not exercisable until after the Stockholder Approval Date.
• The offering is a best efforts offering, and there is no guarantee that the company will sell all of the securities being offered.
• The offering is expected to close on January 31, 2025, unless terminated earlier, which may create uncertainty for investors.

Risks

• The warrants are not exercisable until after the Stockholder Approval Date.
• The offering is a best efforts offering, and there is no guarantee that the company will sell all of the securities being offered.
• The offering is expected to close on January 31, 2025, unless terminated earlier, which may create uncertainty for investors.
• The company may not use the proceeds effectively, which could affect results of operations and cause the stock price to decline.
• The company may need additional funds to support operations, and such funding may not be available on acceptable terms, or at all.

Future Outlook

The company intends to use the net proceeds from this offering and the concurrent private placement, together with its existing cash and cash equivalents, to fund its commercial sales, research and development, and for working capital and other general corporate purposes.

Industry Context

This offering is taking place in the context of Allurion Technologies seeking to expand its market presence and fund its operations, including the commercialization of its products and research and development efforts.

Comparison to Industry Standards

• The offering structure, including the use of common stock, pre-funded warrants, and common stock purchase warrants, is a common method for raising capital in the biotechnology and medical device industries.
• The inclusion of a cashless exercise option for the Series B warrants is a feature that is sometimes seen in warrant offerings, which can be attractive to investors.
• The involvement of Roth Capital Partners, LLC as the exclusive placement agent is typical for offerings of this type and size.
• The indication of interest from RTW Investments, LP is a common occurrence in these types of offerings, where existing investors may participate in the capital raise.

Related Party Transactions

• Certain funds affiliated with RTW Investments, LP have indicated an interest in investing $1.5 million in this offering and a concurrent private placement of preferred stock and warrants.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The offering will provide the company with additional capital to fund its operations.
• The offering may impact the market price of the company's common stock.

Next Steps

• The company will seek Stockholder Approval for the issuance of shares upon exercise of the warrants.
• The company will file a final prospectus with the SEC.
• The company will close the offering on or about January 31, 2025, unless terminated earlier.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, offering, capital raise, stockholder approval, exercise price, placement agent, securities, RTW Investments